Founded in Japan in 1890, Santen Pharmaceutical is a leading provider of innovative therapies for patients suffering from eye diseases. The recent inauguration of its new European Headquarters in Geneva is part of its global expansion strategy, as indicated by its president and CEO Akira Kurokawa in a press release: “Our ambition for 2020 is to become a specialized company with a global presence and overseas sales to represent 40% -50% of our revenues. This new European HQ is a key element in that strategy. Switzerland and Geneva in particular offers an outstanding location from which to expand our commercial footprint, and to benefit from the life-science expertise and networks established here.”
In an interview with Geneva-based newspaper la Tribune de Genève, Shigeo Taniuchi, Head of Santen Europe, explains how the company finalized its decision to settle in Geneva: “In March 2014, we contacted the Swiss Business Hub Japan, the Japanese representative of Switzerland Global Enterprise (S-GE). In a few days, all the meetings were scheduled (in Switzerland). We met with many canton representatives. In Geneva, we were impressed with the precision, the professionalism and the understanding towards the needs of an organization like ours. In one month, we had discussed with all the key people allowing us to make a decision.”
Pierre Maudet, Minister of the Department of Security and Economy for the Republic and Canton of Geneva, said he was “delighted” by the arrival of a world leader in ophthalmology, which will undoubtedly enrich the local life sciences cluster.